DDCB coordinates infrastructure and expertise in the areas of drug discovery and chemical biology and makes it available to the scientific community. The DDCB platform provides services in assay development and chemical screening from medium to high throughput with a broad range of technologies including the DDCB-developed drug sensitivity and resistance testing platform. Our service portfolio also includes antibacterial screening, specialized assays for novel materials, repurposing of drugs, virtual screening, chemoinformatics, medicinal chemistry, as well as open access to a large national chemical collection, translational support and user base education.


Contact details


Platform Chair


Päivi Tammela
paivi.tammela@helsinki.fi


Nodes


Node/Host UniversityNode PI
HiLIFE – FIMM High Throughput Biomedicine Unit (HiLIFE-HTB), UH
Päivi Tammela
paivi.tammela@helsinki.fi
HiLIFE - Faculty of Pharmacy (HiLIFE-PHAR), UH
Henri Xhaard
henri.xhaard@helsinki.fi
Biocenter Kuopio – Molecular Modelling and Drug Design (BCK-PMC), UEF
Antti Poso
antti.poso@uef.fi
BioCity Turku – Turku Screening Unit/UTU (BCT-TSU), UTU
Michael Courtney
miccou@utu.fi
BioCity Turku – SBL-Computational Drug Design (BCT-SBL-CDD), ÅAU
Outi Salo-Ahen
outi.salo-ahen@abo.fi
Biocenter Kuopio – Medicinal Chemistry and Organic Synthesis Facilities (BCK-MCOS), UEF
Kristiina M. Huttunen
kristiina.huttunen@uef.fi

UEF: University of Eastern Finland; UH: University of Helsinki;  UTU: University of Turku, ÅAU: Åbo Akademi University



Services


  • Project and assay guidance and development support – all sites
  • Chemical screening and profiling – FIMM and Faculty of Pharmacy, UH; BioCity Turku
  • Drug sensitivity and resistance screening (DSRT) and drug repurposing – FIMM, UH
  • Imaging-based high-throughput screening – FIMM, UH, BioCity Turku
  • Antimicrobial screening and follow-up assays – Faculty of Pharmacy, UH
  • Chemoinformatics, molecular modeling, and virtual screening – Biocenter Kuopio, Faculty of Pharmacy, UH, and BioCity Turku – SBL-Computational Drug Design, ÅAU
  • Synthesis of novel drug candidates and hit/lead optimisation – Biocenter Kuopio - UEF-MCOS
  • Follow-up screening and testing – all sites
  • Access to a large national chemical collection – FIMM

Image

Recent user publications


Momeny M, Tienhaara M, Sharma M, Chakroborty D, Varjus R, Takala I, Merisaari J, Padzik A, Vogt A, Paatero I, Elenius K, Laajala TD, Kurppa KJ, Westermarck J. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO Mol Med. 2024, 16, 1603-1629. doi: 10.1038/s44321-024-00088-0


Ali AE, Li LL, Courtney MJ, Pentikäinen OT, Postila PA. Atomistic simulations reveal impacts of missense mutations on the structure and function of SynGAP1. Brief Bioinform. 2024, 25, bbae458. doi: 10.1093/bib/bbae458


Saadabadi A, Wilkman L, Rantanen M, Koivisto A-P, Salo-Ahen OMH: Structure- and Ligand-Based Virtual Screening for Identification of Novel TRPV4 Antagonists. Molecules. 2025, 30, 100. doi: 10.3390/molecules30010100


Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, Ruokoranta T, Kuusanmäki H, Ikonen N, Sergeev P, Vähä-Koskela M, Giri AK, Vähärautio A, Kontro M, Porkka K, Pitkänen E, Heckman CA, Wennerberg K, Aittokallio T. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones. Nat Commun. 2024, 15, 8579. https://doi.org/10.1038/s41467-024-52980-5


Heininen J, Movahedi P, Kotiaho T, Kostiainen R, Pahikkala T, Teppo J. Targeted and Untargeted Amine Metabolite Quantitation in Single Cells with Isobaric Multiplexing.Chem. Eur. J. 2024, 30, e202403278. https://doi.org/10.1002/chem.202403278


Bogacheva MS, Kuivanen S, Potdar S, Hassinen A, Huuskonen S, Pöhner I, Luck TJ, Turunen L, Feodoroff M, Szirovicza L, Savijoki K, Saarela J, Tammela P, Paavolainen L, Poso A, Varjosalo M, Kallioniemi O, Pietiäinen V, Vapalahti O. Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome. Antiviral Research. 2024, 223, 105813. https://doi.org/10.1016/j.antiviral.2024.105813


Pozzetti L, East MP, Laitinen T, Asquith CRM. TLK2: a target for cancer and viral latency. Nat. Rev. Drug Discov. 2024, 23, 886-886. https://doi.org: 10.1038/d41573-024-00163-8


Pietiäinen V, Polso M, Migh E, Guckelsberger C, Harmati M, Diosdi A, Turunen L, Hassinen A, Potdar S, Koponen A, Sebestyen EG, Kovacs F, Kriston A, Hollandi R, Burian K, Terhes G, Visnyovszki A, Fodor E, Lacza Z, Kantele A, Kolehmainen P, Kakkola L, Strandin T, Levanov L, Kallioniemi O, Kemeny L, Julkunen I, Vapalahti O, Buzas K, Paavolainen L, Horvath P, Hepojoki J. Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2. Cell Rep Methods. 2023, 3, 100565. doi: 10.1016/j.crmeth.2023.100565.

Jokinen EM, Niemeläinen M, Kurkinen ST, Lehtonen JV, Lätti S, Postila PA, Pentikäinen OT, Niinivehmas S. Virtual Screening Strategy to Identify Retinoic Acid-Related Orphan Receptor γt Modulators. Molecules. 2023, 28, 3420. doi: 10.3390/molecules28083420

Asquith CRM, Temme L, East MP, Laitinen T, Pickett J, Kwarcinski FE, Sinha P, Wells CI, Johnson GL, Zutshi R, Drewry DH. Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype. ChemMedChem. 2022, e202200161. doi: 10.1002/cmdc.202200161


Image
Image
Image